At the news
? NEUTRALIMPACT 3/10 8-K filed Apr 13, 2026 at 07:30 ET
Palvella Therapeutics appointed John Doux, M.D., to its Board of Directors as a Class III member, effective April 13, 2026. Dr. Doux brings extensive experience in dermatology, biotech investing, and corporate governance from prior board roles in healthcare companies.
- John Doux, M.D., was appointed to the Board of Directors effective April 13, 2026
- Board size increased from six to seven members
- Dr. Doux is a board-certified dermatologist and healthcare investor at Palo Alto Investors LP
- He previously served on Palvella's board from 2019 to 2022 prior to its reverse merger
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access